Serum biochemical profile in buffalo endometritis and impact of treatment with PGF2α and intrauterine gentamicin infusion on postpartum reproductive performance.

Improving reproductive performance of repeat breeder buffalo cows due to clinical endometritis is crucial in overcoming infertility problems in buffalo cows. The aim of the present study was to use PGF2α and/or gentamicin 10% for treatment of endometritis and to determine biochemical parameters in serum that could be used to diagnose endometritis in buffalo cows. A total of 64 anestrous buffalo cows were assigned into one of five treatment groups: group one (n = 9) buffalo cows were physiological normal cows and served as a control group; group 2 buffalo cows had endometritis, but were not treated (n = 10); group 3 buffalo cows had endometritis and were treated with intrauterine delivery of 100 ml of a 10% gentamicin sulfate solution in three times within 1 week (n = 15); group 4 buffalo cows received two I.M. doses of PGF2α (2 ml Estrumate IM) at the time of corpus luteum dominance (n = 15) (treatment 4 does not make sense as you stated that the cows were in anestrus) on the ovary; group 5 buffalo cows received two IM doses of PGF2α at an 11 day interval and the 10% gentamicin solution as described for group 3. Serum samples were collected from control, pre-treated, and post-treated buffalo cows with endometritis to evaluate the diagnostic biochemical parameters. The days to first estrus (DFE), number of services per conception (S/C), days open (DO), and pregnancy rate (Preg) were the measures for determining reproductive performance for the buffalo cows. The buffalo cows treated by gentamicin and PGF2 exhibited their first estrus earlier than cows in the other four groups of cows. The number of days open for control cows was greater (P < 0.05) than for the other groups and the control cows, as were the number of services per conception (P < 0.05) and pregnancy rate (30%: P < 0.05). The receiver operating characteristic (ROC) curve was used to identify biochemical parameters in serum to predict endometritis. Creatine kinase (CK), aspartate aminotransferase (AST), and concentrations of total bilirubin and immunoglobulins in serum were greater (P < 0.05), while serum albumin values were lower (P < 0.05) in serum of buffalo cows with endometritis. From the ROC analyses, CK was the most predictable biomarker for endometritis with an area under the curve of 0.889, sensitivity of 80%, and specificity of 100% (P < 0.001). In conclusion, the use of gentamicin and PGF2 for treatment of endometritis improves the reproductive performance of buffalo cows, and concentrations of CK serve as an aid for diagnosing endometritis.Graphical abstract.

Bovine Respiratory Disease Vaccination Against Viral Pathogens: Modified-Live Versus Inactivated Antigen Vaccines, Intranasal Versus Parenteral, What Is the Evidence?

Vaccination of cattle against viral respiratory pathogens to minimize losses associated with bovine respiratory disease (BRD) is a common practice among producers and veterinarians. Three different calf populations in which BRD is most prevalent (recently weaned beef calves, preweaning beef calves, and young dairy calves) are the principal focus of morbidity and mortality prevention through vaccination; however, the evidence of vaccination efficacy is inconsistent in the literature. This review addresses the evidence of efficacy of vaccination in the prevention or reduction of naturally occurring and experimentally induced BRD in each calf group.

Adjuvant intraperitoneal ceftriaxone in the treatment of septic peritonitis in horses.

BACKGROUND: Intraperitoneal administration of ceftriaxone maintains therapeutic abdominal concentrations for 24 hours in healthy horses. Therefore, it is a possible treatment for septic peritonitis. The aim of this study was to evaluate the efficacy of ceftriaxone as an adjuvant treatment in horses with septic peritonitis. METHODS: Twenty-six horses with clinical signs, sonography and/or laboratory findings of septic peritonitis were included. Peritoneal fluid was collected for microbiological culture and in vitro microbial sensitivity profile assessment. Daily intraperitoneal administration of ceftriaxone (25 mg/kg) was initiated with supportive and systemic antimicrobial treatment. The animals were divided into three groups: group 1-gastrointestinal tract injuries and abdominal surgery (excluding perforations/ruptures); group 2-not related to changes in the gastrointestinal tract; group 3-secondary to intestinal rupture and/or faeces contamination. RESULTS: The mean success rate of the treatment was 77 per cent (20/26 animals), with success rates of 84.6 per cent in group 1; 87.5 per cent, group 2; and 40 per cent, group 3. CONCLUSIONS: This is the first study to report adjuvant intraperitoneal treatment ceftriaxone for septic peritonitis in horses and indicates that this treatment can successfully treat septic peritonitis in horses.

Short communication: Production of antimicrobial peptide S100A8 in the goat mammary gland and effect of intramammary infusion of lipopolysaccharide on S100A8 concentration in milk.

This study aimed to determine the production site of antimicrobial peptide S100A8 in the goat mammary gland and changes in its concentration in milk after lipopolysaccharide (LPS) challenge. Sixteen Tokara goats were used in this study for mammary gland tissue, blood leukocyte, and milk somatic cell collection and LPS challenge. The mRNA expression and protein localization of S100A8 in the mammary gland parenchyma and teat, blood leukocytes, and milk somatic cells were examined by reverse-transcription PCR and immunohistochemistry. The S100A8 concentration in milk was measured at 0 to 144 h after intramammary challenge of LPS by enzyme immunoassay. The mRNA of S100A8 was expressed in the parenchyma and teat, leukocytes isolated from blood, and milk somatic cells. Antimicrobial peptide S100A8 was immunolocalized in the outermost layer of the teat skin of udders with and without LPS infusion, whereas in the mammary gland it was immunolocalized only in the leukocytes infiltrated in the alveoli after LPS infusion. Antimicrobial peptide S100A8 was also immunolocalized in the blood and milk leukocytes. The number of S100A8-positive cells in milk was higher than that in blood. The concentration of S100A8 in milk increased significantly at 72 h after intramammary infusion of LPS. These results suggest that S100A8 is produced in the leukocytes and that its secretion into milk is affected by LPS stimulation.

Effects of pulse-dose ruminal infusion of butyrate on plasma glucagon-like peptide 1 and 2 concentrations in dairy calves.

Feeding of butyrate was found to have a positive effects in enhancing gut development and improving growth performance of calves. Equally, glucagon-like peptide 1 and 2 (GLP-1 and GLP-2), secreted from gastrointestinal L-cells in response to nutrient intake, were found to play a significant role in regulating blood glucose homeostasis and improving gut health. However, limited information is available about the relationship between butyrate and release of GLP-1 and GLP-2 in dairy calves. The objective of this study was to evaluate the effects of a pulse-dose ruminal infusion of butyrate on plasma GLP-1 and GLP-2 concentrations in dairy calves. Five ruminally cannulated mature Holstein bull calves (7.2 ± 0.10 mo, and 330 ± 16.0 kg of body weight; mean ± standard deviation) were used in a 5 × 5 Latin square with 4-d periods. On d 1 of each period at 0800 h, calves were ruminally infused with 1 of 5 treatments: 0 (saline), 0.3, 0.6, 0.9, and 1.2 g of butyrate per kg of body weight. Before butyrate infusion, calves were not offered feed overnight, and sequential blood and rumen fluid samples were taken before and after infusion on d 1 of each period. Ruminal butyrate and total volatile fatty acid concentrations increased linearly (2.65, 12.19, 20.99, 30.19, and 36.30; 23.68, 33.07, 40.94, 51.13, and 56.31 µmol/mL, for butyrate and total volatile fatty acids, respectively) in a dose-dependent manner, whereas propionate and isobutyrate increased quadratically. Ruminal and plasma butyrate, ß-hydroxybutyrate, GLP-1, GLP-2, insulin, and glucose concentrations were all affected by treatment, time (except GLP-2), and interaction of treatment with time (except GLP-1). The area under the curve (AUC) summarized at different time points relative to the baseline (AUC30, AUC60, AUC120, and AUC240) for ruminal and plasma butyrate, and BHB, increased linearly with the dose of butyrate infused. However, AUC30, AUC60, AUC120, and AUC240 for plasma GLP-2 concentration were affected in a cubic manner unlike the linear effect on AUC30 and AUC60 for GLP-1. Plasma GLP-2 was not correlated with plasma butyrate (r = 0.16), GLP-1 (r = 0.03), or BHB (r = -0.05). This findings suggest that pulse-dosing of butyrate slightly increased both GLP-1 and GLP-2 concentrations at specific time points and this might be promoted by direct or indirect effect of butyrate on the intestinal L-cells.

Effects of oral versus parenteral cobalamin supplementation on methylmalonic acid and homocysteine concentrations in dogs with chronic enteropathies and low cobalamin concentrations.

The objective of this study was to compare the effects of parenteral (PE) versus oral (PO) cobalamin supplementation on serum methylmalonic acid (MMA) and homocysteine (HCY) concentrations in dogs with hypocobalaminaemia. Thirty-six dogs with serum cobalamin concentrations below 285ng/L (reference interval (RI): 244-959ng/L) were treated with PO (0.25-1.0mg daily) or PE cobalamin (0.25-1.2mg/injection) using a block-randomized schedule. Serum MMA and HCY concentrations were analysed at day 0, 28 and 90 after start of supplementation. There was no significant difference between the PO and PE group regarding serum MMA or HCY concentrations at any time point. Median (range, P comparing baseline and 28 days, P comparing 28days and 90 days) serum MMA concentrations (nmol/L; RI 415-1193) were 932 (566-2468) in the PO and 943 (508-1900) in the PE group at baseline, respectively, 705 (386-1465, P<0.0001) and 696 (377-932, P<0.0001) after 28 days, and 739 (450-1221, P=0.58) and 690 (349-1145, P=0.76) after 90 days. Serum HCY concentrations (median (range), P comparing baseline and 28 days, P comparing 28days and 90 days, µmol/L; RI 5.9-31.9) in the PO and PE groups were 12.2 (3.3-62.2) and 8.4 (3.7-34.8) at baseline, 12.5 (5.0-45.0, P=0.61) and 8.0 (3.8-18.3, P=0.28) after 28 days, and 17.7 (7.3-60.0 P=0.07) and 12.4 (6.3-33.1, P=0.0007) after 90 days, respectively. Oral and parenteral cobalamin supplementation had the same effect on serum MMA concentrations in this group of dogs.

Comparative efficacy of modified-live and inactivated vaccines in boosting responses to bovine respiratory syncytial virus following neonatal mucosal priming of beef calves.

Bovine respiratory syncytial virus (BRSV) is the leading cause of viral pneumonia in calves, making young passively immune calves candidates for vaccination, and raising issues concerning boosting of neonatally primed responses. To address this, 18, 2-month-old Angus-cross passively immune beef heifer calves that had been primed at birth with a combination viral intranasal vaccine were administered either a parenteral combination vaccine containing modified-live (MLV) BRSV or a similar vaccine containing inactivated BRSV. At 6 months of age, these calves and 2 controls that received only the MLV at 2 months of age were challenged with BRSV via aerosol. Two calves, 1 control, and 1 MLV-boosted, developed severe respiratory disease and required euthanasia; the remaining calves developed no or mild respiratory disease and recovered. Calves that received the inactivated booster had significantly higher arterial oxygen concentrations on Day 7 after challenge and had anamnestic BRSV-specific IgG and neutralizing antibodies after challenge; the MLV-boosted calves did not. These data suggest that adjuvanted inactivated parenteral BRSV vaccines administered at 2 months of age may provide better boosting for neonatally mucosally primed calves.

Efficacité comparée des vaccins vivants modifiés et des vaccins inactivés pour améliorer la réponse au virus respiratoire syncytial bovin après la sensibilisation active néonatale des muqueuses chez les veaux de boucherie. Le virus respiratoire syncytial bovin (VRS) est la cause principale de pneumonie virale chez les veaux, ce qui rend des jeunes veaux à immunité passive des candidats pour la vaccination et soulève des enjeux liés à l'amélioration de la réponse des nouveau-nés sensibilisés. Dans le but d'aborder cette situation, 18 veaux de boucherie de race croisée Angus âgés de 2 mois ayant une immunité passive, qui avaient été sensibilisés activement à la naissance à l'aide d'une combinaison de vaccins intranasaux viraux, ont reçu soit un vaccin combiné parentéral contenant le VRS modifié vivant (VMV) ou un vaccin semblable contenant le VRS inactivé. À l'âge de 6 mois, ces veaux et deux témoins qui avaient reçu seulement le VNV à l'âge de 2 mois, ont été exposés au VRS par voie aérosol. Deux veaux, un témoin et un animal ayant reçu le rappel VMV, ont développé une maladie respiratoire grave et ont dû être euthanasiés; les autres animaux ont développé une maladie respiratoire légère et se sont rétablis ou n'ont manifesté aucun symptôme. Les veaux qui avaient reçu le rappel inactivé affichaient des concentrations d'oxygène significativement supérieures dans le sang artériel le jour 7 après le test et présentaient des anticorps neutralisants et anamnestiques spécifiques aux VRS après le test, contrairement aux veaux ayant reçu le rapport VNV. Ces données suggèrent que les vaccins VRS parentéraux inactivés avec adjuvants administrés à l'âge de 2 mois peuvent offrir une meilleure protection pour les veaux sensibilisés activement à la naissance sur les muqueuses.(Traduit par Isabelle Vallières).

Temporal effects of ruminal propionic acid infusion on feeding behavior of Holstein cows in the postpartum period.

The objective of this study was to determine the temporal effects of intraruminal infusion of propionic acid at the initiation of meals on feeding behavior of cows in the postpartum period. Propionic acid derived from ruminal fermentation can reduce energy intake of dairy cows. The suppression of appetite by propionic acid is likely caused by a signal related to the hepatic oxidation of fuels. Greater propionate flux to the liver is expected to result in faster oxidation of acetyl coenzyme A, which can stimulate satiety and reduce feed intake. Therefore, the rate of propionate supply to the liver, within the timeframe of meals, might be an important limitation to feed intake. Our hypothesis was that faster rate of propionate infusion during meals would decrease meal size and feed intake by decreasing the time required to stimulate satiety within a meal. Six ruminally cannulated, multiparous Holstein cows in the postpartum period were used in a duplicated 3 × 3 Latin square design experiment balanced for carryover effects. Treatments included control (no infusion) or 1.25 mol of propionic acid infused over 5 min (FST) or 15 min (SLW) at each meal. Infusions were initiated at the conditioned meal at feeding (1200 h) and were triggered at each spontaneous meal for 22 h. Contrary to our hypothesis, SLW decreased meal size 29% (0.87 vs. 1.23 kg of dry matter) compared with FST, and FST decreased meal frequency 27% (8.5 vs. 11.2 per d) compared with SLW. Dry matter intake was similar between FST and SLW, but propionic acid decreased dry matter intake 46% compared with control. A potential explanation is that FST resulted in greater liver bypass of propionate compared with SLW, extending anaplerosis of the tricarboxylic acid cycle, hepatic oxidation of acetyl coenzyme A, and satiety over a longer time after meals.

Infusion of butyrate affects plasma glucose, butyrate, and ß-hydroxybutyrate but not plasma insulin in lactating dairy cows.

The objective of this study was to investigate the effects on plasma metabolites and rumen traits when butyrate was infused into the rumen or abomasum of lactating cows. Jugular catheters were inserted into 5 ruminally fistulated Holstein cows [94.2 ± 26.3 DIM; 717 ± 45 kg of body weight (BW); mean ± SD] in a 5 × 5 Latin square with 3-d periods. Cows were infused for 24 h with 1 of 5 treatments: water (CON), 1 g/kg of BW of butyrate infused into either the abomasum (A1) or rumen (R1), or 2 g/kg of BW of butyrate infused into either the abomasum or rumen. Sodium butyrate was the source of butyrate and NaCl was added to the CON, A1, and R1 treatments to provide the same amount of sodium as supplied by the sodium butyrate treatment in the 2-g treatments. Plastisol flanges were inserted into the abomasum to allow infusion to the abomasum and peristaltic pumps provided continuous infusion at 9.3 mL/min for all treatments. The concentration of NaCl and sodium butyrate was varied in the infusate to provide the correct infusion amount. Rumen fluid samples were collected at -2, -1, 0, 1, 2, 3, 4, 6, 8, 12, 18, 24, 28, and 32 h relative to start of infusion. Serial blood samples were collected at -2, -1, 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 26, 28, and 32 h relative to start of infusion. Compared with CON, infusing butyrate increased both plasma butyrate and plasma ß-hydroxybutyrate (BHB), whereas plasma glucose decreased. Increasing butyrate infusion from 1 to 2 g increased plasma butyrate, tended to decrease plasma glucose, and tended to increase plasma BHB. Compared with abomasal infusion, rumen infusion of butyrate increased rumen butyrate, did not affect plasma glucose, and tended to increase plasma BHB. Treatment had no effect on plasma insulin. Results demonstrated that site of infusion and amount of butyrate affected several plasma metabolites when butyrate was infused in lactating dairy cows over a period of 24 h.

Efficacy assessment of an intramammary treatment with a new recrystallized enrofloxacin vs ceftiofur and parenteral enrofloxacin in dairy cows with nonsevere clinical mastitis.

A recrystallized form of enrofloxacin as dehydrate-HCl (enro-C) was assessed for bacteriological and clinical cure efficacies in Holstein-Friesian cows affected of nonsevere clinical mastitis. Treatments were enro-Csusp (n = 81), treated with a pharmaceutical suspension of enro-C/quarter; group enro-Cpd (n = 80) treated as above, but using enro-C powder suspended in water; group CF (n = 65), treated with ceftiofur HCl/quarter; and group enroR (n = 66), treated with standard enrofloxacin solution (5 mg/kg, intramuscular). Cows had a mean milk production of 31 L/day and were 2-3 lactational periods old. Treatments were administered every 24 hr for 3 days. Groups treated with enro-C exhibited statistically significant (p > .05) better clinical cure as compared to groups treated with CF or enroR (95.06%, 96.25%, 67.79%, and 57.55%, for enro-Csusp , enro-Cpd , CF, and enroR , respectively). In contrast, probability of bacteriological cure was not statistically different among treatments. Yet, the outstanding clinical and bacteriological cure rates obtained for enro-C for nonsevere cases of mastitis is superior to previously reported data for parenteral enrofloxacin and other antibacterial-intramammary treatments. Impact of using enro-C on the rate and pattern of bacterial resistance, somatic cell counts and milk electric conductivity, must be studied. Also, the use of enro-C for complicated cases of mastitis should be studied and milk withdrawal times must be accurately established.

Relative bioavailability of carnitine delivered by ruminal or abomasal infusion or by encapsulation in dairy cattle.

Two studies were designed to evaluate the relative bioavailability of l-carnitine delivered by different methods in dairy cattle. In experiment 1, 4 Holstein heifers were used in a split-plot design to compare ruminally or abomasally infused l-carnitine. The study included 2 main-plot periods, with infusion routes allocated in a crossover design. Within main-plot periods, each of 3 subplot periods consisted of 4-d infusions separated with 4-d rest periods. Subplot treatments were infusion of 1, 3, and 6 g of l-carnitine/d in conjunction with 6 g/d of arabinogalactan given in consideration of eventual product manufacturing. Doses increased within a period to minimize carryover risk. Treatments were solubilized in 4 L of water and delivered in two 10-h infusions daily. Blood was collected before the start of infusion period and on d 4 of each infusion period to obtain baseline and treatment l-carnitine concentrations. There was a dose × route interaction and route effect for increases in plasma carnitine above baseline, with increases above baseline being greater across all dose levels when infused abomasally compared with ruminally. Results demonstrated superior relative bioavailability of l-carnitine when ruminal exposure was physically bypassed. In experiment 2, 56 lactating Holstein cows (143 ± 72 d in milk) were used in 2 cohorts in randomized complete block designs (blocked by parity and milk production) to evaluate 2 rumen-protected products compared with crystalline l-carnitine. Treatments were (1) control, (2) 3 g/d of crystalline l-carnitine (crystalline), (3) 6 g/d of crystalline, (4) 5 g/d of 40COAT (40% coating, 60% l-carnitine), (5) 10 g/d of 40COAT, (6) 7.5 g/d of 60COAT (60% coating, 40% l-carnitine), and (7) 15 g/d of 60COAT. Treatments were top-dressed to diets twice daily. Each cohort used 14-d and included a 6-d baseline measurement period with the final 2 d used for data and sample collection, and an 8-d treatment period with the final 2 d used for data and sample collection. Plasma, urine, and milk samples were analyzed for l-carnitine. Crystalline and 40COAT linearly increased plasma l-carnitine, and 60COAT tended to linearly increase plasma l-carnitine. Total excretion (milk + urine) of l-carnitine averaged 1.52 ± 0.04 g/d in controls, increased linearly with crystalline and 40COAT, and increased quadratically with 60COAT. Crystalline increased plasma l-carnitine and l-carnitine excretion more than 40COAT and 60COAT. In conclusion, preventing ruminal degradation of l-carnitine increased delivery of bioavailable carnitine to cattle, but effective ruminal protection and postruminal bioavailability is challenging.

Early-lactation extended pirlimycin therapy against naturally acquired Staphylococcus aureus intramammary infections in heifers: A randomized controlled trial.

The primary objective of the current study was to evaluate cure rate following an early-lactation extended intramammary pirlimycin treatment on heifers naturally infected by Staphylococcus aureus. The secondary objective was to assess Petrifilm Staph Express (3M Microbiology, St. Paul, MN) count plate characteristics when used in a protocol for early-lactation detection of infected quarters in heifers. Milk samples were collected from heifers (n = 946) in the first few days following calving (mean = 5 d). Heifers with laboratory-confirmed S. aureus intramammary infection (n = 72) were randomly allocated into 2 groups. The treatment group (n = 54 quarters from 38 heifers) received an intramammary infusion of 50 mg of pirlimycin once per day for 8 consecutive days in infected quarters. The control group (n = 44 quarters from 34 heifers) did not receive any treatment. Treatment success was defined as having negative culture results for S. aureus in all 3 post-treatment quarter milk samples collected on d 17, 24, and 31 post-treatment. Treatment group mammary quarters showed a statistically significant higher cure rate (64.8%) compared with the control group (34.1%). A total of 38% of quarters identified as S. aureus-positive using the Petrifilm Staph Express count plate were in fact identified as non-aureus staphylococci on routine laboratory-based bacteriological culture. The current study demonstrates that a higher cure rate for S. aureus IMI can be achieved in dairy heifers if an extended treatment protocol is put in place soon after calving. Use of Petrifilm Staph Express count plate for identification of S. aureus-infected heifers could lead to unnecessary treatments because of false-positive results.

Evaluation of the sterility of single-dose medications used in a multiple-dose fashion.

Bacterial proliferation was evaluated in single-dose medications used in a multi-dose fashion and when medications were intentionally inoculated with bacteria. Of 5 experimentally punctured medications, 1 of 75 vials (50% dextrose) became contaminated. When intentionally inoculated, hydroxyethyl starch and heparinized saline supported microbial growth. Based on these findings, it is recommended that hydroxyethyl starch and heparinized saline not be used in a multi-dose fashion.

Évaluation de la stérilité des médicaments à dose unique utilisés pour plusieurs doses. On a évalué la prolifération bactérienne dans les médicaments à dose unique utilisés pour plusieurs doses et lorsque les médicaments sont intentionnellement inoculés avec des bactéries. Parmi les cinq médicaments ayant subi une ponction expérimentale, 1 des 75 flacons (50 % dextrose) a été contaminé. Lorsqu'ils étaient inoculés intentionnellement, l'hydroxyéthylcellulose et le soluté physiologique hépariné supportaient la croissance microbienne. En se basant sur ces résultats, il est recommandé que l'hydroxyéthylcellulose et le soluté physiologique hépariné ne soient pas utilisés pour plusieurs doses.(Traduit par Isabelle Vallières).

Effectiveness of pre-peritoneal continuous wound infusion with lidocaine for pain control following ovariohysterectomy in dogs.

This study compared the post-operative analgesic efficacy of continuous lidocaine administration with that of intramuscular (IM) methadone in dogs undergoing ovariohysterectomy. Thirty-eight dogs were divided randomly into two groups. Following surgery, the lidocaine group (L) received a continuous lidocaine infusion (2 mg/kg/h) through a wound catheter inserted in the pre-peritoneal space; the control group (C) received methadone (0.2 mg/kg IM). A dynamic and interactive visual analogue scale (DIVAS), the Scale-Form Glasgow Composite Measure Scale (CMPS-SF), mechanical wound thresholds, heart rate, respiratory rate and blood pressure were assessed pre-operatively and 2, 4, 6, 18, and 24 h after surgery. The presence of the wound catheter prevented the evaluator from remaining blinded to group allocations. Plasma lidocaine and cortisol levels were measured 2, 6, 18, and 24 h after surgery. There were no intergroup differences in any pain assessment scale scores at any time point. Stable intravenous lidocaine levels were observed. Four animals in the control group but none in the lidocaine group required rescue analgesia. There were no differences in complication rates between groups. Continuous locoregional lidocaine delivered via a wound catheter between the parietal peritoneum and abdominal muscle offers effective analgesia in dogs during ovariohysterectomy and appears to be a promising analgesic option in veterinary surgery.

Effects of abomasal infusion of conjugated linoleic acids, Sterculia foetida oil, and fish oil on production performance and the extent of fatty acid Δ9-desaturation in dairy cows.

The purpose of this study was to determine the effects of conjugated linoleic acid (CLA), Sterculia foetida oil (STO), and fish oil (FO) on milk yield and composition, milk FA profile, Δ(9)-desaturation activity, and mammary expression of 2 isoforms of stearoyl-coenzyme A desaturase (SCD-1 and SCD-5) in lactating dairy cows. Eight multiparous Holstein cows (69 ± 13 d postpartum) were used in a double 4 × 4 Latin square design with 28-d periods. For the first 14 d of each period, cows received an abomasal infusion of (1) 406 g of a saturated fatty acid (SFA) supplement (112 g of 16:0 + 230 g of 18:0) used as a control (CTL), (2) 36 g of a CLA supplement (13.9 g of trans-10,cis-12 18:2) + 370 g of SFA, (3) 7 g of STO (3.1g of 19:1 cyclo) + 399 g of SFA, or (4) 406 g of FO (55.2 g of cis-5,-8,-11,-14,-17 20:5 + 59.3 g of cis-4,-7,-10,-13,-16,-19 22:6). Infusions were followed by a 14-d washout interval. Compared with CTL, STO decreased milk yield from 38.0 to 33.0 kg/d, and increased milk fat concentration from 3.79 to 4.45%. Milk fat concentration was also decreased by CLA (2.23%) and FO (3.34%). Milk fat yield was not affected by STO (1,475 g/d) compared with CTL (1,431 g/d), but was decreased by CLA (774 g/d) and FO (1,186 g/d). Desaturase indices for 10:0, 12:0, and 20:0 were decreased, whereas the extent of desaturation of 14:0, 16:0, 17:0, and 18:0 was not affected by CLA treatment compared with CTL. Infusion of STO significantly decreased all calculated desaturase indices compared with CTL; the 14:0 index was reduced by 80.7%. Infusion of FO decreased the desaturase indices for 10:0, 14:0, 20:0, trans-11 18:1, and 18:0. The effect of FO on the 14:0 index indicates a decrease in apparent Δ(9)-desaturase activity of 30.2%. Compared with CTL, mammary mRNA abundance of SCD-1 was increased by STO (+30%) and decreased by CLA (-24%), whereas FO had no effect. No effect was observed on mRNA abundance of SCD-5. In conclusion, abomasal infusion of CLA, STO, and FO were shown to exhibit varying and distinct effects on desaturase indices, an indicator of apparent SCD activity, and mammary mRNA abundance of SCD-1.

Efficacy of 5-day parenteral versus intramammary benzylpenicillin for treatment of clinical mastitis caused by gram-positive bacteria susceptible to penicillin in vitro.

The efficacy of parenteral (intramuscular) or intramammary (IMM) benzylpenicillin treatment for clinical mastitis caused by gram-positive bacteria susceptible to penicillin in vitro was investigated. Cows with clinical mastitis in 1 udder quarter were randomly placed into 2 treatment groups. The preliminary bacteriological diagnosis of intramammary infection (IMI) was based on on-farm culturing, and the bacteriological diagnoses were later confirmed by a quantitative PCR assay. Clinical mastitis caused by gram-positive bacteria susceptible to benzylpenicillin was treated with penicillin via either the parenteral route (20mg/kg) or IMM route (600mg) once per day for 5d. The outcome of the treatment was evaluated 3 to 4wk after the onset of the treatment. The affected quarter was examined to assess the clinical cure, and milk samples were collected from the affected quarter to determine the bacteriological cure and milk N-acetyl-ß-d-glucosaminidase activity. The survival and the composite milk somatic cell counts of the treated cows were followed up for 6 and 3mo after treatment, respectively. A total of 140 cows with clinical mastitis were included in the study, 61 being treated with benzylpenicillin parenterally and 79 via the IMM route. From all quarters treated, 108 of 140 (77.1%) were cured clinically and 77 of 140 (55.0%) were cured bacteriologically. The route of treatment did not significantly affect the outcome of the treatment; 80.3% of the quarters with parenteral treatment and 74.7% of the quarters with IMM treatment showed a clinical cure, and 54.1 and 55.7% a bacteriological cure, respectively. The milk N-acetyl-ß-d-glucosaminidase activity was significantly lower in the quarters with a clinical or bacteriological cure than in the quarters with no cure. The 6-mo survival and the proportion of cows with composite milk somatic cell counts <200,000/mL among the treated cows during the 3-mo follow-up period did not significantly differ between the treatment groups. In conclusion, the outcome of either parenteral or IMM benzylpenicillin treatment of clinical mastitis caused by penicillin-susceptible bacteria was similar.

Balling gun-induced trauma in cattle: clinical presentation, diagnosis and prevention.

Pharyngeal trauma in cattle can occur during the administration of oral medication using a balling gun. The number of cases of severe complications due to bolus application that have been referred to our hospital has increased from nil between 1996 and 2008 to three or four per year. In our experience, reports by bovine veterinarians of patients with severe and often fatal pharyngeal trauma, which were not referred to the clinic, have become more common in recent years as well. The incidence of this complication is likely to be higher than this number of referrals suggests. Diagnosis without the help of imaging techniques, such as radiography and endoscopy, may be difficult, especially in cases where exploration of the pharynx cannot be carried out, or is unable to confirm the absence or presence of a lesion. Prognosis is often poor in cases where perforation has been confirmed. Boluses are increasingly administered by the owners or farm personnel without the supervision of a veterinarian. In order to prevent losses due to balling gun-induced injuries, the veterinarian plays a crucial role in giving advice to his clients. Five cases of cattle suffering from varying degrees of balling gun-induced trauma are presented, and consideration is given to incorrect application techniques.

Intraperitoneal medetomidine: a novel analgesic strategy for postoperative pain management in pregnant sheep.

The absorption of medetomidine released by continuous infusion from an osmotic pump in the abdominal cavity was studied in pregnant sheep during the 24 h postoperative period. Additionally pain and sedation was assessed. Eleven sheep were studied: six were treated with a medetomidine loaded osmotic pump delivering 10 µL/h (3 µg/kg/h medetomidine); and five with a saline loaded osmotic pump (control). Serial blood samples were taken and analysed to determine plasma medetomidine levels. Medetomidine was absorbed from the peritoneal cavity and a steady plasma concentration was achieved within 10 h, mean (SD) peak concentration was 2.87 (0.22) ng/mL. Sheep receiving medetomidine analgesia had significantly lower pain scores at 10 h than controls. Four control sheep required rescue analgesia, compared with 0 in the treatment group. Delivery of 3 µg/kg/h medetomidine by an intraperitoneal osmotic pump to pregnant sheep in the 24 h postoperative period provides adequate plasma concentrations of medetomidine for analgesia without sedation.

Duodenal infusion of α-linolenic acid affects fatty acid metabolism in the mammary gland of lactating dairy cows.

Increasing the concentration of α-linolenic acid (LNA; 18:3 cis-9,cis-12,cis-15) in blood might affect fatty acid (FA) metabolism in the mammary gland of dairy cows. The objective was to determine the effects of different arterial concentrations of 18:3 cis-9,cis-12,cis-15 (18:3n-3) achieved via duodenal infusions with LNA on mammary uptake [assessed via arterial-rectificative venous concentration (AC-RVC) differences], synthesis of FA, and mammary gland FA balance in lactating dairy cows. Four primiparous lactating Chinese Holstein cows fitted with duodenal cannulas were administered 2 treatments in a crossover design: LNA-rich FA infusion at varying concentrations (0, 100, 200, and 300 g/d) versus basal infusate control. Arterial concentration of 18:3n-3 increased quadratically (29.24, 134.1, 218.3, and 219.3mg/L of plasma) as LNA infusion levels increased from 0 to 300 g/d. The mammary extraction rate and uptake of 18:3n-3 increased linearly as LNA infusion increased. The AC-RVC difference of total FA and 18:3n-3 increased more rapidly than arterial concentrations with all treatments. Increasing LNA infusion increased linearly the balance of 10:0 and 12:0, whereas it decreased linearly the 14:1 and 15:0 balances. Increasing arterial concentration of 18:3n-3 affects uptake and synthesis of FA in the mammary gland of lactating dairy cows. It is also suggested that the use of AC-RVC difference maybe an acceptable way to investigate mammary gland uptake and synthesis of FA.